DOCSLIB.ORG

Development of Pharmacological Magnetic Resonance Imaging Methods and Their Application to the Investigation of Antipsychotic Drugs: a Dissertation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Development of Pharmacological Magnetic Resonance Imaging Methods and Their Application to the Investigation of Antipsychotic Drugs: a Dissertation University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2006-07-08 Development of Pharmacological Magnetic Resonance Imaging Methods and their Application to the Investigation of Antipsychotic Drugs: a Dissertation Karl F. Schmidt University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Animal Experimentation and Research Commons, Chemical Actions and Uses Commons, and the Diagnosis Commons Repository Citation Schmidt KF. (2006). Development of Pharmacological Magnetic Resonance Imaging Methods and their Application to the Investigation of Antipsychotic Drugs: a Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/w7am-qc46. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/ 114 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. A Dissertation Presented By Karl F. Schmidt Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY July 8, 2006 Program in Neuroscience COPYRIGHT Portions of this dissertation appear in the following publications and copyrighted manuscripts: Schmidt KF, Febo M, Shen Q, Luo F, Sicard KM, Ferris CF, Stein EA, Duong TQ. Hemodynamic and metabolic changes induced by cocaine in anesthetized rat observed with multimodal functional MRI. Psychopharmacology (Berl) 185: 479-86 (2006) Liu ZM, Schmidt KF, Sicard KM, Duong TQ. Imaging oxygen consumption in forepaw somatosensory simulation in rats under isoflurane anesthesia. Magn Reson Med 52: 277-285 (2004) Schmidt KF, Lemdiasov RA, Brevard M; Chen W, Fox GB, King JA, Ludwig R, Ferris CF. Simultaneous measurement of spin-echo BOLD and cerebral blood flow in the conscious rat using a three coil imaging and restraint system. Copyright © 2006 Journal of Neuroscience Methods, under review Ferris CF, Febo M, Luo F, Schmidt K, Brevard M, Harder JA, Kulkarni P, Messenger T, King JA. Functional magnetic resonance imaging in conscious animals: a new tool in behavioural neuroscience research. J Neuroendocrinol. 2006 May;18(5):307-18. ii Development of Pharmacological Magnetic Resonance Imaging Methods and Their Application to the Investigation of Antipsychotic Drugs A Dissertation Presented By Karl F. Schmidt Approved as to style and content by: David Weaver, Ph.D., Chair of Committee Jean King, Ph.D., Member of Committee Glenn Gaudette, Ph.D., Member of Committee Daniel Kilpatrick, Ph.D., Member of Committee Lino Becerra, Ph.D., External Member of Committee Craig Ferris, Ph.D., Thesis Advisor Anthony Carruthers, Ph.D., Dean of the Graduate School of Biomedical Sciences Ph.D. Program in Neuroscience June 16, 2006 iii ACKNOWLEDGMENTS I have been unusually fortunate as a graduate student to have had the opportunity to train under the direction of two mentors with very different interests and expertise. Dr. Timothy Duong was responsible for my training in my first years at UMASS Medical School and, following his progression to Emory University, I have had the great fortune to complete my training under the direction of Dr. Craig Ferris. I owe a tremendous debt of gratitude to both mentors, for their invaluable instruction in the technical aspects of MRI and in the application of MRI to pertinent problems in neuroscience. For years now, Dr. David Weaver has provided me with tireless and unwavering support in my scholastic and research efforts, without which I am confident that my progress would have stalled or failed, long ago. Similarly, the additional members of my research committee, Drs. Jean King, Glenn Gaudette, and Josie Harder, have provided me with the critical direction and support that I have needed in my research efforts, and I am truly grateful. I would like to thank the members of the examination committee, some of whom have already suffered through too many of my presentations, for contributing their valuable time in this final exercise, especially Drs. Lino Becerra and Daniel Kilpatrick. My colleagues at the CCNI have provided me with a broader education than I could possibly have anticipated. To be surrounded by such diverse medical and technical expertise has been a rare opportunity, and I thank Dr. Marcelo Febo, Mat Brevard, Tara Messenger, Dr. Li Zhixin, Dr. Ken Sicard, Dr. Praveen Kulkarni, Dr. Steve Bird, Dr. Nils iv Henninger, Dr. Wei Chen, and Dr. Feng Luo (now at Abbott Laboratories), as well as Govind Nair (now at Emory University) for their help and instruction over the past years. I owe this opportunity to pursue my doctorate to my mentors at Harvard Medical School, Drs. Mitch Albert, Yanping Sun, and Mary Mazzanti, for their training in prior years. I sincerely appreciate the support and direction given by Dr. Tony Carruthers in my first months at UMASS, and on a continuing basis thereafter, as well as the loving support and encouragement of my family. Several studies were made possible with the gracious financial support of Abbott Laboratories, and the valuable direction of Drs. Gerard Fox, Yanping Luo, Pamela Skoubis, Vincent Hradil, and Chih-Liang Chin. Overall, funding for this research was provided by Abbott Laboratories, the American Heart Association (SDG-0430020N), the National Institute on Drug Abuse (R01- DA13517), the National Institutes of Health (R01-EY014211), the University of Massachusetts Medical School, and the Whitaker Foundation (RG-02-0005). Finally, the word support does not begin to describe the emotional investment and daily contributions of another that have ultimately made this pursuit possible. What small portion of this effort that is mine to give, is dedicated to my loving wife, Rebecca. v ABSTRACT Pharmacological magnetic resonance imaging (phMRI) is the use of functional MRI techniques to elucidate the effects that psychotropic drugs have on neural activity within the brain; it is an emerging field of research that holds great potential for the investigation of drugs that act on the central nervous system by revealing the changes in neural activity that mediate observable changes in behavior, cognition, and perception. However, the realization of this potential is hampered by several unanswered questions: Are the MRI measurements reliable surrogates of changing neural activity in the presence of pharmacological agents? Is it relevant to investigate psychiatric phenomena such as reward or anxiolysis in anesthetized, rather than conscious animals? What are the methods that yield reproducible and meaningful results from phMRI experiments, and are they consistent in the investigations of different drugs? The research presented herein addresses many of these questions with the specific aims of 1) Developing pharmacological MRI methodologies that can be used in the conscious animal, 2) Validating these methodologies with the investigation of a non-stimulant, psychoactive compound, and vi 3) Applying these methodologies to the investigation of typical and atypical antipsychotic drugs, classes of compounds with unknown mechanisms of therapeutic action Building on recent developments in the field of functional MRI research, we developed new techniques that enable the investigator to measure localized changes in metabolism commensurate with changing neural activity. We tested the hypothesis that metabolic changes are a more reliable surrogate of changes in neural activity in response to a cocaine challenge, than changes observed in the blood-oxygen-level-dependent (BOLD) signal alone. We developed a system capable of multi-modal imaging in the conscious rat, and we tested the hypothesis that the conscious brain exhibits a markedly different response to systemic morphine challenge than the anesthetized brain. We identified and elucidated several fundamental limitations of the imaging and analysis protocols used in phMRI investigations, and developed new tools that enable the investigator to avoid common pitfalls. Finally, we applied these phMRI techniques to the investigation of neuroleptic compounds by asking the question: does treatment with typical or atypical antipsychotic drugs modulate the systems in the brain which are direct or indirect (i.e. downstream) substrates for a dopaminergic agonist? The execution of this research has generated several new tools for the neuroscience and drug discovery communities that can be used in neuropsychiatric investigations into the action of psychotropic drugs, while the results of this research provide evidence that supports several answers to the questions that currently limit the utility of phMRI investigations. Specifically, we observed that metabolic change can be measured to vii resolve discrepancies between anomalous BOLD signal changes and underlying changes in neural activity in the case of systemically administered cocaine. We found clear differences in the response to systemically administered morphine between conscious and anesthetized rats, and observed that only conscious animals exhibit a phMRI response that can be explained by the pharmacodynamics of morphine and corroborated by behavioral observations. We identified fundamental and drug-dependent limitations in the protocols used to perform phMRI investigations, and designed
Load more

Recommended publications
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • The Past and Future of Novel, Non-Dopamine-2 Receptor Therapeutics for Schizophrenia: a Critical and Comprehensive Review T
    Journal of Psychiatric Research 108 (2019) 57–83 Contents lists available at ScienceDirect Journal of Psychiatric Research journal homepage: www.elsevier.com/locate/jpsychires The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review T ∗ Ragy R. Girgis ,1, Anthony W. Zoghbi1, Daniel C. Javitt, Jeffrey A. Lieberman The New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, N.Y, USA ARTICLE INFO ABSTRACT Keywords: Since the discovery of chlorpromazine in the 1950's, antipsychotic drugs have been the cornerstone of treatment Schizophrenia of schizophrenia, and all attenuate dopamine transmission at the dopamine-2 receptor. Drug development for Experimental treatments schizophrenia since that time has led to improvements in side effects and tolerability, and limited improvements Clinical trials in efficacy, with the exception of clozapine. However, the reasons for clozapine's greater efficacy remain unclear, Dopamine despite the great efforts and resources invested therewith. We performed a comprehensive review of the lit- Glutamate erature to determine the fate of previously tested, non-dopamine-2 receptor experimental treatments. Overall we Novel therapeutics included 250 studies in the review from the period 1970 to 2017 including treatments with glutamatergic, serotonergic, cholinergic, neuropeptidergic, hormone-based, dopaminergic, metabolic, vitamin/naturopathic, histaminergic, infection/inflammation-based, and miscellaneous mechanisms. Despite there being several pro- mising targets, such as allosteric modulation of the NMDA and α7 nicotinic receptors, we cannot confidently state that any of the mechanistically novel experimental treatments covered in this review are definitely effective for the treatment of schizophrenia and ready for clinical use.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,937,096 B2 Smith-Swintosky Et Al
    US008937096B2 (12) United States Patent (10) Patent No.: US 8,937,096 B2 Smith-Swintosky et al. (45) Date of Patent: *Jan. 20, 2015 (54) USE OF BENZO-FUSED HETEROCYLE 5,238,945 A 8/1993 Perregaard SULFAMIDE DERVATIVES FOR THE 35:25 A 3. SEF al. TREATMENT OF MANIA AND BIPOLAR 5. A 36 ST DSORDER 5,312.925 A 5/1994 Allen et al. 5,384.327 A 1/1995 Constanzo et al. (75) Inventors: Virginia L. Smith-Swintosky, Hatfield, 5,387,700 A 2/1995 Maryanoff et al. PA (US); Allen B. Reitz, Lansdale, PA 2. A 3. S.A.al. (US) 5,753,694. A 5/1998 Shank 73) Assi Ph tica NVB 5,760,007 A 6/1998 Shank et al. ( SS1gnee: SS e , Seerse 5,780,650 A 7/1998 Furukawa et al. (BE) 5,935,933 A 8, 1999 Shank et al. 5.998,380 A 12/1999 Ehrenberg et al. (*) Notice: Subject to any disclaimer, the term of this 6,071,537 A 6/2000 Shank patent is extended or adjusted under 35 E. f 13s. East al. U.S.C. 154(b) by 1888 days. 6,91163 B 22001 Cottrell 6,211,241 B1 4/2001 Islam et al. This patent is Subject to a terminal dis- 6,319,903 B1 1 1/2001 Carrazana et al. claimer. 6,322,503 B1 1 1/2001 Sparhawk, Jr. 6,323,236 B2 11/2001 McElroy (21) Appl. No.: 11/612,222 6,391,877 B1 5/2002 Islam et al. 6,503,884 B1 1/2003 Ehrenberg et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Molecular Targets of Atypical Antipsychotics: from Mechanism of Action to Clinical Differences
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Queen Mary Research Online JPT-07243; No of Pages 23 Pharmacology & Therapeutics xxx (2018) xxx–xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences Stefano Aringhieri a, Marco Carli a, Shivakumar Kolachalam a, Valeria Verdesca a, Enrico Cini a, Mario Rossi b, Peter J. McCormick c, Giovanni U. Corsini a, Roberto Maggio d, Marco Scarselli a,⁎ a Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy b Institute of Molecular Cell and Systems Biology, University of Glasgow, UK c William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK d Biotechnological and Applied Clinical Sciences Department, University of L'Aquila, Italy article info abstract Keywords: The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug clozapine has been Atypical antipsychotics a revolutionary pharmacological step for treating psychotic patients as these allow a significant recovery not only Clozapine in terms of hospitalization and reduction symptoms severity, but also in terms of safety, socialization and better Monoamine receptors rehabilitation in the society. Regarding the mechanism of action, AAPs are weak D2 receptor antagonists and they Dimerization act beyond D2 antagonism, involving other receptor targets which regulate dopamine and other neurotransmit- Biased agonism ters. Consequently, AAPs present a significant reduction of deleterious side effects like parkinsonism, Therapeutic drug monitoring hyperprolactinemia, apathy and anhedonia, which are all linked to the strong blockade of D2 receptors.
    [Show full text]
  • Antipsychotic Dosing: Extended, and Transient Philip Seeman 1, Gary Remington 1, 2, 3
    Clinical Concepts Antipsychotic Dosing: Extended, and Transient Philip Seeman 1, Gary Remington 1, 2, 3 New Ways of Antipsychotic Dosing In addition, while there is preclinical information in animals Considering the few new medications being developed that stimulation of mGluR2/3 receptors might be therapeu- for schizophrenia, it is recognized that novel avenues of tic, the clinical efficacy of this approach has not yet been research are needed for drug treatment of schizophrenia. clearly established (4). While current antipsychotic drugs primarily block dopa- While interference with dopamine transmission at D2 is mine D2 receptors or interfere with dopamine neurotrans- the minimum drug requirement for treating schizophrenia, mission (1, 2), many drugs for non-D2 pathways and re- there are new ways and new drugs that optimize the dosing ceptors have been tested as possible antipsychotics, but not of patients to minimize side effects and rehospitalization. with much success. These include antagonists or agonists at These new ways are based on the fact that some antipsychot- receptors for D1 (SCH 23390), D3 (BP897; ABT925), D4 ics, such as clozapine, quetiapine, amisulpride, remoxipride (fananserin/sonepiprazole), cannabinoids (rimonabant), and amoxapine, attach to the D2 receptor in vitro for brief neurokinins (SR142801; osanetant), neurotensin (SR48692), periods of time (half-times of 15 to 66 seconds) before dis- glycine transport inhibitors, ampakines (CX516), and se- sociating from the D2 receptors (5-7). In fact, the transient rotonin (MDL100907; SR 46349B). The hypoglutamate hy- attachment (a few hours in vivo) of quetiapine to D2 has pothesis of schizophrenia suggests that low stimulation of been confirmed in patients (8).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Molecular Targets of Atypical Antipsychotics: from Mechanism of Action to Clinical Differences
    JPT-07243; No of Pages 23 Pharmacology & Therapeutics xxx (2018) xxx–xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences Stefano Aringhieri a, Marco Carli a, Shivakumar Kolachalam a, Valeria Verdesca a, Enrico Cini a, Mario Rossi b, Peter J. McCormick c, Giovanni U. Corsini a, Roberto Maggio d, Marco Scarselli a,⁎ a Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy b Institute of Molecular Cell and Systems Biology, University of Glasgow, UK c William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK d Biotechnological and Applied Clinical Sciences Department, University of L'Aquila, Italy article info abstract Keywords: The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug clozapine has been Atypical antipsychotics a revolutionary pharmacological step for treating psychotic patients as these allow a significant recovery not only Clozapine in terms of hospitalization and reduction symptoms severity, but also in terms of safety, socialization and better Monoamine receptors rehabilitation in the society. Regarding the mechanism of action, AAPs are weak D2 receptor antagonists and they Dimerization act beyond D2 antagonism, involving other receptor targets which regulate dopamine and other neurotransmit- Biased agonism ters. Consequently, AAPs present a significant reduction of deleterious side effects like parkinsonism, Therapeutic drug monitoring hyperprolactinemia, apathy and anhedonia, which are all linked to the strong blockade of D2 receptors. This review revisits previous and current findings within the class of AAPs and highlights the differences in terms of receptor properties and clinical activities among them.
    [Show full text]